Comparative Pharmacology
Head-to-head clinical analysis: ERYTHRA DERM versus ERYTHROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHRA DERM versus ERYTHROMYCIN.
ERYTHRA-DERM vs ERYTHROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. It also exhibits anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and bacterial lipase production.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the translocation step.
Apply a thin layer to the affected area(s) twice daily. For topical use only. Adult dose is 2% solution or ointment.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life of 2-4 hours; prolonged to 5-6 hours in hepatic impairment.
Clinical Note
moderateErythromycin + Norfloxacin
"Erythromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateErythromycin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Erythromycin."
Clinical Note
moderateErythromycin + Ibandronate
"Erythromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateErythromycin + Indapamide
Terminal half-life is 1.4-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in anuria.
Primarily biliary fecal elimination (60-70%); renal excretion of unchanged drug <15%.
Primarily hepatic (biliary) elimination; approximately 2-5% excreted unchanged in urine, 30-60% excreted in feces via bile.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic
"Erythromycin may increase the QTc-prolonging activities of Indapamide."